Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QN-030a
- Development stage
- Phase 1
- Lead developer
- Qihan Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
QN-030a is an allogeneic natural killer (NK) cell therapy developed by Quacell Biotech for the treatment of hematological malignancies, specifically acute myeloid leukemia (AML). The therapy utilizes healthy donor-derived NK cells that are expanded and activated ex vivo before administration. These NK cells are designed to exert anti-tumor effects through innate immune recognition and the subsequent release of cytotoxic granules, such as perforin and granzymes, to induce apoptosis in malignant cells. Clinical development has targeted both minimal residual disease (MRD) and relapsed or refractory cases of AML, aiming to provide a graft-versus-leukemia effect without the need for patient-specific cell engineering.
- Other names
- QN-030aQN030aQN 030a
Beyond the preview
Go deeper on QN-030a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QN-030a.